1ProLynx LOGO.png
ProLynx et Daiichi Sankyo annoncent la mise au point d’une technologie permettant d’étendre la demi-vie des petites molécules dans l’œil
August 29, 2018 23:39 ET | ProLynx LLC
SAN FRANCISCO, 30 août 2018 (GLOBE NEWSWIRE) -- ProLynx et Daiichi Sankyo Company, Limited ont annoncé aujourd’hui la publication d’un article dans le journal TVST intitulé « A controlled...
1ProLynx LOGO.png
ProLynx und Daiichi Sankyo geben die Entwicklung einer Technologie zur Verlängerung der Halbwertszeit von kleinen Molekülen im Auge bekannt
August 29, 2018 23:39 ET | ProLynx LLC
SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- ProLynx und Daiichi Sankyo Company, Limited, gaben heute die Veröffentlichung eines Artikels in der Zeitschrift TVST mit dem Titel „A controlled...
1ProLynx LOGO.png
August 29, 2018 23:39 ET | ProLynx LLC
サンフランシスコ発, Aug. 30, 2018 (GLOBE NEWSWIRE) -- プロリンクス (ProLynx) と第一三共株式会社 (Daiichi Sankyo Company, Limited) は本日、TVST誌に「A controlled release system for long-acting intravitreal delivery of small...
1ProLynx LOGO.png
ProLynx and Daiichi Sankyo announce the development of technology for half-life extension of small molecules in the eye
August 29, 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, Aug. 29, 2018 (GLOBE NEWSWIRE) -- ProLynx and Daiichi Sankyo Company, Limited, announced today the publication of a paper in the journal TVST entitled “A controlled release system for...
April 10, 2018 17:57 ET | ProLynx LLC
サンフランシスコ発 , April 11, 2018 (GLOBE NEWSWIRE) -- プロリンクス (ProLynx LLC、カリフォルニア州サンフランシスコ) は、現在MDアンダーソン (MD Anderson) で実施中の第1相試験のDNA損傷エンハンサーPLX038 (PEG〜SN-38) に対して、認可通知を受けたことを発表した。PLX038は、DNA複製中にトポイソメラーゼ1...
ProLynx announces al
ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
April 10, 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1...
1ProLynx LOGO.png
ProLynx extends lead in half-life extension platform technology – Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
April 03, 2018 09:00 ET | ProLynx LLC
SAN FRANCISCO, April 03, 2018 (GLOBE NEWSWIRE) -- ProLynx announced today the publication of a paper demonstrating its leading capabilities to exploit primary deuterium kinetic isotope effects...
1ProLynx LOGO.png
September 26, 2017 04:16 ET | ProLynx LLC
サンフランシスコ発, Sept. 26, 2017 (GLOBE NEWSWIRE) -- プロリンクス (ProLynx) は本日、単一の媒体で2つ以上の薬剤のデリバリーをコントロールする技術プラットフォームを拡張するために、NIHから中小企業技術革新制度 (Small Business Innovation Research、SBIR)...
1ProLynx LOGO.png
ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
September 25, 2017 09:00 ET | ProLynx LLC
SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control...
1ProLynx LOGO.png
ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye
June 19, 2017 09:00 ET | ProLynx LLC
SAN FRANCISCO, June 19, 2017 (GLOBE NEWSWIRE) -- Today ProLynx LLC announced a collaboration with Daiichi Sankyo Company, Limited to evaluate its drug delivery linker technology in the eye.    In...